BioLine RX LtdNASDAQ:BLRXNASDAQ FSI:D. Deficient (Issuer failed to meet continued listing requirements)
- LAST PRICE0.7340
- TODAY'S CHANGE (%)-0.0116 (-1.5558%)
- Bid / Lots0.7300/ 21
- Ask / Lots0.8200/ 43
- Open / Previous Close0.7522 / 0.7456
- Day Range
- 52 Week Range
- Volume161,157
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | BLRX |
|---|---|---|
| 09:32 ET | 933 | 0.7517 |
| 09:41 ET | 1940 | 0.7535 |
| 09:43 ET | 800 | 0.75 |
| 09:48 ET | 5840 | 0.75 |
| 09:56 ET | 150 | 0.774699 |
| 09:59 ET | 685 | 0.7747 |
| 10:01 ET | 4800 | 0.7521 |
| 10:03 ET | 128 | 0.75 |
| 10:06 ET | 10800 | 0.75 |
| 10:08 ET | 2504 | 0.7316 |
| 10:14 ET | 2900 | 0.73 |
| 10:21 ET | 2700 | 0.7301 |
| 10:24 ET | 23600 | 0.7301 |
| 10:26 ET | 100 | 0.7327 |
| 10:32 ET | 10048 | 0.73989 |
| 10:33 ET | 230 | 0.73162 |
| 10:39 ET | 320 | 0.7398 |
| 10:44 ET | 1700 | 0.732 |
| 10:50 ET | 100 | 0.735899 |
| 10:51 ET | 100 | 0.732 |
| 10:53 ET | 250 | 0.7397 |
| 11:04 ET | 650 | 0.734542 |
| 11:15 ET | 4925 | 0.7334 |
| 11:20 ET | 900 | 0.732 |
| 11:24 ET | 100 | 0.732 |
| 11:36 ET | 5078 | 0.732 |
| 11:38 ET | 337 | 0.7334 |
| 11:42 ET | 700 | 0.734294 |
| 11:44 ET | 1440 | 0.734 |
| 11:45 ET | 425 | 0.734699 |
| 11:49 ET | 5155 | 0.735 |
| 11:54 ET | 4600 | 0.7429 |
| 12:02 ET | 150 | 0.75 |
| 12:09 ET | 133 | 0.75 |
| 12:23 ET | 235 | 0.748067 |
| 12:32 ET | 200 | 0.738 |
| 12:39 ET | 400 | 0.738 |
| 12:48 ET | 900 | 0.7399 |
| 12:54 ET | 3390 | 0.735 |
| 12:59 ET | 100 | 0.7369 |
| 01:06 ET | 500 | 0.735 |
| 01:10 ET | 3655 | 0.734 |
| 01:12 ET | 100 | 0.737 |
| 01:26 ET | 250 | 0.734905 |
| 01:28 ET | 100 | 0.734905 |
| 01:35 ET | 300 | 0.734 |
| 01:44 ET | 973 | 0.7397 |
| 01:50 ET | 200 | 0.7378 |
| 02:29 ET | 1100 | 0.734 |
| 02:33 ET | 400 | 0.7394 |
| 02:44 ET | 1014 | 0.7378 |
| 02:45 ET | 100 | 0.7396 |
| 03:02 ET | 3550 | 0.737 |
| 03:09 ET | 2100 | 0.74 |
| 03:14 ET | 100 | 0.74 |
| 03:20 ET | 500 | 0.74485 |
| 03:32 ET | 12903 | 0.736 |
| 03:34 ET | 1500 | 0.7361 |
| 03:43 ET | 1300 | 0.737853 |
| 03:52 ET | 600 | 0.736 |
| 03:54 ET | 1600 | 0.736 |
| 03:56 ET | 1806 | 0.736 |
| 03:57 ET | 6171 | 0.734 |
| 03:59 ET | 4165 | 0.734 |
Today
May 30, 2024
BioLineRx Announces Clinical Trial Agreement with St. Jude Children's Research Hospital, Inc. to Evaluate Motixafortide for CD34+ Hematopoietic Stem Cell (HSC) Mobilization For Gene Therapy Applications in Sickle Cell Disease (SCD), from 7:00AM ET on Thursday May 30, 2024 by Dow Jones
7:00AM ET on Thursday May 30, 2024 by Dow Jones
May 29, 2024
DJ BioLine RX Price Target Maintained With a $21.00/Share by HC Wainwright & Co., from 10:34AM ET on Wednesday May 29, 2024 by Dow Jones
10:34AM ET on Wednesday May 29, 2024 by Dow Jones
May 28, 2024
BioLineRx Reports First Quarter 2024 Financial Results and Recent Corporate and Portfolio Updates, from 7:00AM ET on Tuesday May 28, 2024 by Dow Jones
7:00AM ET on Tuesday May 28, 2024 by Dow JonesPress Release: BioLineRx Reports First Quarter 2024 Financial Results and Recent Corporate and Portfolio Updates, from 7:00AM ET on Tuesday May 28, 2024 by Dow Jones
7:00AM ET on Tuesday May 28, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
BioLine RX Ltd | 58.4M | -1.0x | --- |
LAVA Therapeutics NV | 59.4M | -2.3x | --- |
Dyadic International Inc | 63.7M | -7.9x | --- |
Kronos Bio Inc | 47.5M | -0.4x | --- |
Kezar Life Sciences Inc | 50.5M | -0.5x | --- |
Cue Biopharma Inc | 79.3M | -1.5x | --- |
Company Information
BioLine RX Ltd is an Israel-based clinical-stage biopharmaceutical company focused on oncology. The Company is commited into in-license novel compounds, develop them through clinical stages, and then partner with pharmaceutical companies for further clinical development andcommercialization. The Company is commited into two projects: Motixafortide (BL-8040), which is a cancer therapy platform , and AGI-134, an immunotherapy treatment.
Contact Information
- Headquarters
- Modi'in Technology Park 2 HaMa'ayan StreetMODIIN, Israel 7177871
- Phone
- ---
- Fax
- ---
Executives
- Chairman of the Board
- Aharon Schwartz
- Chief Executive Officer
- Philip Serlin
- Chief Financial Officer
- Mali Zeevi
- Vice President - Development
- Ella Sorani
- Vice President-Clinical & Medical Affairs
- Abi Vainstein-Haras
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $58.4M |
|---|---|
Revenue (TTM) | $11.7M |
Shares Outstanding | 79.9M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.54 |
EPS | $-0.76 |
Book Value | $0.18 |
P/E Ratio | -1.0x |
Price/Sales (TTM) | 5.0 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -391.76% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
